Asset Details
Do you wish to reserve the book?
BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors
Do you wish to request the book?
BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors
2019
Overview
Heterozygous germline mutations in
BRCA2
predispose to breast and ovarian cancer. Contrary to non-cancerous cells, where
BRCA2
deletion causes cell cycle arrest or cell death, tumors carrying
BRCA2
inactivation continue to proliferate. Here we set out to investigate adaptation to loss of BRCA2 focusing on genome-wide transcriptome alterations. Human cells in which BRCA2 expression is inhibited for 4 or 28 days are subjected to RNA-seq analyses revealing a biphasic response to
BRCA2
abrogation. The early, acute response consists of downregulation of genes involved in cell cycle progression, DNA replication and repair and is associated with cell cycle arrest in G1. Surprisingly, the late, chronic response consists predominantly of upregulation of interferon-stimulated genes (ISGs). Activation of the cGAS-STING-STAT pathway detected in these cells further substantiates the concept that
BRCA2
abrogation triggers cell-intrinsic immune signaling. Importantly, we find that treatment with PARP inhibitors stimulates the interferon response in cells and tumors lacking BRCA2.
BRCA2 plays important roles in cell physiology by promoting DNA replication and DNA double-strand breaks repair. Here the authors, reveal the impact of BRCA2 depletion on the cell transcriptional program with activation of the innate immune response that is potentiated by PARP inhibitor treatments.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 13/106
/ 38
/ 38/91
/ Animals
/ Breast
/ Breast Neoplasms - immunology
/ Cancer
/ Carcinoma, Non-Small-Cell Lung - genetics
/ Carcinoma, Non-Small-Cell Lung - immunology
/ Colorectal Neoplasms - genetics
/ Colorectal Neoplasms - immunology
/ DNA
/ Female
/ Gene Expression Regulation, Neoplastic
/ Genes
/ Genomes
/ Humanities and Social Sciences
/ Humans
/ Mutation
/ RNA
/ Science
/ Tumors
